Tissue transglutaminase inhibits autophagy in pancreatic cancer cells

Molecular Cancer Research

Volumn 5, Issue 3, 2007, Pages 241-249

  Akar, Ugur ^a   Ozpolat, Bulent ^a   Mehta, Kapil ^a   Fok, Jansina ^a   Kondo, Yasuko ^a   Lopez Berestein, Gabriel ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN KINASE C; ROTTLERIN; SMALL INTERFERING RNA; TISSUE TRANSGLUTAMINASE; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHAGY; CANCER CELL; CELL GROWTH; CONTROLLED STUDY; CYTOPLASM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACETOPHENONES; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BENZOPYRANS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; MEMBRANE PROTEINS; PANCREATIC NEOPLASMS; PROTEIN KINASE C-DELTA; PROTEIN KINASE INHIBITORS; RNA, SMALL INTERFERING; TRANSGLUTAMINASES;

EID: 34147161141     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-06-0229     Document Type: Article

References (40)

1. Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 2003;4:140-56.
2. Mhaouty-Kodja S. Ghα/tissue transglutaminase 2: an emerging G protein in signal transduction. Biol Cell 2004;96:363-7.
3. Hasegawa G, Suwa M, Ichikawa Y, et al. A novel function of tissue-type transglutaminase: protein disulphide isomerase. Biochem J 2003;373:793-803.
4. Mishra S, Murphy LJ. The p53 oncoprotein is a substrate for tissue transglutaminase kinase activity. Biochem Biophys Res Commun 2006;339: 726-30.
5. Kang SK, Kim DK, Damron DS, Baek KJ, Im MJ. Modulation of intracellular Ca(2+) via α(1B)-adrenoreceptor signaling molecules, Gα(h) (transglutaminase II) and phospholipase C-δ1. Biochem Biophys Res Commun 2002;293:383-90.
6. Fesus L, Szondy Z. Transglutaminase 2 in the balance of cell death and survival. FEBS Lett 2005;579:3297-302.
7. Zemskov EA, Janiak A, Hang J, Waghray A, Belkin AM. The role of tissue transglutaminase in cell-matrix interactions. Front Biosci 2006;11:1057-76.
8. Oliverio S, Amendola A, Di Sano F, et al. Tissue transglutaminase- dependent posttranslational modification of the retinoblastoma gene product in promonocytic cells undergoing apoptosis. Mol Cell Biol 1997;17:6040-8.
9. Herman JF, Mangala LS, Mehta K. Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 2006;25:3049-58.
10. Mehta K, Fok J, Miller FR, Koul D, Sahin AA. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 2004;10:8068-76.
11. Han JA, Park SC. Reduction of transglutaminase 2 expression is associated with an induction of drug sensitivity in the PC-14 human lung cancer cell line. J Cancer Res Clin Oncol 1999;125:89-95.
12. Elsasser HP, MacDonald R, Dienst M, Kern HF. Characterization of a transglutaminase expressed in human pancreatic adenocarcinoma cells. Eur J Cell Biol 1993;61:321-8.
13. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003;63:8614-22.
14. Mann AP, Verma A, Sethi G, et al. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-κB in cancer cells: delineation of a novel pathway. Cancer Res 2006;66:8788-95.
15. Verma A, Wang H, Manavathi B, et al. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res 2006;66:10525-33.
16. Koivunen J, Aaltonen V, Peltonen J. Protein kinase C (PKC) family in cancer progression. Cancer Lett 2006;235:1-10.
17. Wrede CE, Dickson LM, Lingohr MK, Briaud I, Rhodes CJ. Fatty acid and phorbol ester-mediated interference of mitogenic signaling via novel protein kinase C isoforms in pancreatic β-cells (INS-1). J Mol Endocrinol 2003;30:271-86.
18. Jackson DN, Foster DA. The enigmatic protein kinase Cδ: complex roles in cell proliferation and survival. FASEB J 2004;18:627-36.
19. La Porta CA, Di Dio A, Porro D, Comolli R. Overexpression of novel protein kinase Cδ in BL6 murine melanoma cells inhibits the proliferative capacity in vitro but enhances the metastatic potential in vivo. Melanoma Res 2000;10:93-102.
20. Gschwendt M, Muller HJ, Kielbassa K, et al. Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun 1994;199:93-8.
21. Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000;19:5720-8.
22. Daido S, Kanzawa T, Yamamoto A, Takeuchi H, Kondo Y, Kondo S. Pivotal role of the cell death factor BNIP3 in ceramide-induced autophagic cell death in malignant glioma cells. Cancer Res 2004;64:4286-93.
23. Kirisako T, Baba M, Ishihara N, et al. Formation process of autophagosome is traced with Apg8/Aut7p in yeast. J Cell Biol 1999;147:435-46.
24. Toth S, Nagy K, Palfia Z, Rez G. Cellular autophagic capacity changes during azaserine-induced tumour progression in the rat pancreas. Up-regulation in all premalignant stages and down-regulation with loss of cycloheximide sensitivity of segregation along with malignant transformation. Cell Tissue Res 2002;309:409-16.
25. Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005;5:726-34.
26. Kroemer G, Jaattela M. Lysosomes and autophagy in cell death control. Nat Rev Cancer 2005;5:886-97.
27. Edinger AL, Thompson CB. Defective autophagy leads to cancer. Cancer Cell 2003;4:422-4.
28. Mehta K, Fok JY, Mangala LS. Tissue transglutaminase: from biological glue to cell survival cues. Front Biosci 2006;11:173-85.
29. Arico S, Petiot A, Bauvy C, et al. The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 2001;276:35243-6.
30. Takeuchi H, Kondo Y, Fujiwara K, et al. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 2005;65:3336-46.
31. Paglin S, Lee NY, Nakar C, et al. Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells. Cancer Res 2005;65:11061-70.
32. Liang XH, Jackson S, Seaman M, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999;402:672-6.
33. Pattingre S, Tassa A, Qu X, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005;122:927-39.
34. Sarang Z, Molnar P, Nemeth T. Tissue transglutaminase (TG2) acting as G protein protects hepatocytes against Fas-mediated cell death in mice. Hepatology 2005;42:578-87
35. Oliverio S, Amendola A, Rodolfo C, Spinedi A, Piacentini M. Inhibition of "tissue" transglutaminase increases cell survival by preventing apoptosis. J Biol Chem 1999;274:34123-8.
36. He H, Dang Y, Dai F, et al. Post-translational modifications of three members of the human MAP1LC3 family and detection of a novel type of modification for MAP1LC3B. J Biol Chem 2003;278:29278-87.
37. 120 for lipidation and targeting to autophagosomal membranes. J Biol Chem 2004;279:47704-10.
38. Daido S, Yamamoto A, Fujiwara K, Sawaya R, Kondo S, Kondo Y. Inhibition of the DNA-dependent protein kinase catalytic subunit radiosensitizes malignant glioma cells by inducing autophagy. Cancer Res 2005; 65:4368-75.
39. Lu L, Osmond DG. Apoptosis during B lymphopoiesis in mouse bone marrow. J Immunol 1997;158:5136-45.
40. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 2004;11:448-57.